Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Convection-enhanced Delivery of Interleukin-13 Receptor-directed Cytotoxin for Malignant Glioma Therapy*

1 Jun 2006

Abstract excerpt

The treatment of patients with malignant brain tumors, in particular glioblastoma multiforme (GBM) is very challenging because of their diffuse infiltrative nature and the cytological heterogeneity. The median survival of patients with newly diagnosed GBM is only 12-15 months, and only 8-12% of them survive for two years. Novel approaches for brain tumor therapy are needed. Recently, targeted therapies have...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to CAR-T cell therapy research
Share to Immunotherapy and Immune Responses
Share to Toxin Mechanisms and Immunotoxins

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 16700620
DOI: 10.1177/153303460600500307

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 5 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Convection-enhanced Delivery of Interleukin-13 Receptor-directed Cytotoxin for Malignant Glioma Therapy*PMID 16700620Read ↗

Gene therapy-mediated delivery of targeted cytotoxins for glioma therapeutics.Semantic proximity Read ↗

Molecular targeting of malignant gliomas with novel multiply-mutated interleukin 13-based cytotoxins.Semantic proximity Read ↗

Novel anti-brain tumor cytotoxins specific for cancer cells.Semantic proximity Read ↗

In vivo DNA-launched bispecific T cell engager targeting IL-13Rα2 controls tumor growth in an animal model of glioblastoma multiformeSemantic proximity Read ↗

Molecular targeting with recombinant cytotoxins of interleukin-13 receptor alpha2-expressing glioma.Semantic proximity Read ↗

Suppression of human glioma xenografts with second-generation IL13R-specific chimeric antigen receptor-modified T cells.Semantic proximity Read ↗

Improved anti-tumor activity and safety of interleukin-13 receptor targeted cytotoxin by systemic continuous administration in head and neck cancer xenograft model.Semantic proximity Read ↗

Targeting IL-13Ralpha2-positive cancer with a novel recombinant immunotoxin composed of a single-chain antibody and mutated Pseudomonas exotoxin.Semantic proximity Read ↗

Interleukin 13 mutants of enhanced avidity toward the glioma-associated receptor, IL13Ralpha2.Semantic proximity Read ↗

Retargeting interleukin 13 for radioimmunodetection and radioimmunotherapy of human high-grade gliomas.Semantic proximity Read ↗

IL-13Rα2-Targeted Therapy Escapees: Biologic and Therapeutic ImplicationsSemantic proximity Read ↗

A novel ligand delivery system to non-invasively visualize and therapeutically exploit the IL13Rα2 tumor-restricted biomarker.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.